Menu Search
Equities

Hansa Biopharma AB

24H:DUS

Hansa Biopharma AB

Actions
  • Price (EUR)3.47
  • Today's Change-0.02 / -0.57%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 23 2024 18:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Hansa Biopharma AB's revenues fell -13.22% from 154.53m to 134.09m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 611.13m to a larger loss of 831.72m.
Gross margin42.86%
Net profit margin-490.11%
Operating margin-442.93%
Return on assets-67.03%
Return on equity--
Return on investment-88.36%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Hansa Biopharma AB fell by 764.12m. Cash Flow from Investing was negative at 284.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 755.65m for operations while cash used for financing totalled 7.55m.
Cash flow per share--
Price/Cash flow per share--
Book value per share-3.23
Tangible book value per share-5.68
More ▼

Balance sheet in SEKView more

Hansa Biopharma AB has a Debt to Total Capital ratio of 128.95%, a lower figure than the previous year's 471.28%.
Current ratio3.05
Quick ratio3.04
Total debt/total equity--
Total debt/total capital1.29
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.